CCR：抗癌登月計畫(Cancer Moonshot)想要成功不應忽視蛋白組學

文章

醫療新知 > CCR：抗癌登月計畫(Cancer Moonshot)想要成功不應忽視蛋白組學

CCR：抗癌登月計畫(Cancer Moonshot)想要成功不應忽視蛋白組學

29-05-2016

最近一篇發表在國際學術期刊Clinical Cancer Research上的文章指出，美國啟動的抗癌登月計劃除了進行基因組學研究還應當靶向直接推動癌症發展的蛋白質。

奧巴馬總統在今年年初對國會發表的國情咨文中提出國家抗癌登月計劃。

據估計明年將有10億美元投入到該計劃中，主要聚焦在免疫治療，基因組學和聯合治療等幾個方面。來自Inova Schar癌症研究所的Thomas P. Conrads與喬治梅森大學的Emanuel F Petricoin共同發表了這篇最新文章，希望人們對於蛋白質組學在精準醫學，特別是癌症中的重要性投入更多關註。雖然對於癌症登月計劃表示十分讚同，但是他們認為這項計劃不應僅以基因組學為重點，蛋白質組學也是非常重要的一個方面。

作者在文中寫道："畢竟基因組只進行信息的存檔，蛋白質才是真正執行細胞活動的執行者。並且蛋白質構成了大多數用於癌症檢測的生物標記物，還組成了驅動免疫應答以及細胞內外信息交流的抗原，除此之外，幾乎每種標靶治療方法都以蛋白質為靶向目標。因此蛋白質應當成為癌症登月計劃的一個重要研究方向。"

去年12月北弗吉尼亞最大的健康系統Inova與喬治梅森大學建立了夥伴關系，共同進行轉化醫學研究，為了患者利益共享資源。喬治梅森大學的研究人員已經利用蛋白質組學為轉移性乳腺癌病人找到了個體化治療方案，為處於絕境的病人提供了新的治療選擇。

doi: 10.1158/1078-0432.CCR-16-0688

he Obama Administration's Cancer Moonshot: A Call for Proteomics

Thomas P. Conrads1 and Emanuel F Petricoin2

The Cancer Moonshot Program has been launched and represents a potentially paradigm-shifting initiative with the goal to implement a focused national effort to double the rate of progress against cancer. The placement of precision medicine, immunotherapy, genomics, and combination therapies was placed at the central nexus of this initiative. While we are extremely enthusiastic about the goals of the program, it is time we meet this revolutionary project with equally bold and cutting-edge ideas: its time we move firmly into the post-genome era and provide the necessary resources to propel and seize on innovative recent gains in the field of proteomics required for it to stand on equal footing in this narrative as a combined, synergistic engine for molecular profiling. After all, while the genome is the information archive, it is the proteins that actually do the work of the cell and represent the structural cellular machinery. It is the proteins that comprise most of the biomarkers that are measured to detect cancers, constitute the antigens that drive immune response and inter and itntracellular communications, and it is the proteins that are the drug targets for nearly every targeted therapy that is being evaluated in cancer trials today. We believe that a combined systems biology view of the tumor microenvironment that orients cancer studies back to the functional proteome, phosphoproteome and biochemistry of the cell will be essential to deliver on the promise of the Cancer Moonshot program.